Deflazacort
Who holds supplier records for Deflazacort? 6 organisations hold a current record for Deflazacort: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 1 of them holds a valid EU Certificate of Suitability. Recorded organisation countries for current records: Italy (3), India (2) and China (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Deflazacort: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/deflazacort
Reading the evidence
- 6 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 5 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (6)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Deflazacort. Country is the organisation's recorded country, not necessarily the manufacturing site.
- CORAL DRUGS PVT LTDIndia Company GMP cert on recordActive DMF 38936 · latest filing Oct 2023
- NEWCHEM SPAItaly Company GMP cert on recordActive DMF 38357 · latest filing May 2023
- STERLING SPAItaly Company GMP cert on recordActive DMF 30313 · latest filing Mar 2016
- SYMBIOTEC PHARMALAB PRIVATE LTDIndia Company GMP cert on recordActive DMF 24691 · latest filing Mar 2011
- TIANJIN TIANYAO PHARMACEUTICALS CO LTDChinaActive DMF 35535 · latest filing Apr 2021
- ItalyCEP Company GMP cert on record
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (1)
Certificates of Suitability on the EDQM register for Deflazacort, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| EUROAPI ITALY S.R.L. Brindisi | IT | R1-CEP 2000-339 - Rev 04 Deflazacort | Dec 2021 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (1)
Organisations whose Type II DMFs for Deflazacort are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- SCHERING AGInactive DMF 4922 · filed Mar 1983
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (39 listed products contain Deflazacort). The latest listed exclusivity ended 7 Jun 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Deflazacort is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1201891).
Chemical identity
- IUPAC name
- [2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] acetate
- Canonical SMILES
- CC1=N[C@@]2([C@H](O1)C[C@@H]3[C@@]2(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)C(=O)COC(=O)C
- InChIKey
- FBHSPRKOSMHSIF-GRMWVWQJSA-N
- Synonyms
- Azacortinol, Calcort, Deflazacort, DL-458IT, Emflaza, L-5458, MDL 458, MDL-458, MDL458, Zamene, Deflazacortum, Deflazacort Oral
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Corticosteroid
- Mechanism of action
- Corticosteroid Hormone Receptor Agonists
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Deflazacort?
6 organisations hold an active US FDA Type II Drug Master File or a CEP for Deflazacort: CORAL DRUGS PVT LTD (India), NEWCHEM SPA (Italy), STERLING SPA (Italy), SYMBIOTEC PHARMALAB PRIVATE LTD (India), TIANJIN TIANYAO PHARMACEUTICALS CO LTD (China) and EUROAPI ITALY SRL (Italy). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Deflazacort Drug Master Files are active?
CORAL DRUGS PVT LTD (DMF 38936), NEWCHEM SPA (DMF 38357), STERLING SPA (DMF 30313), SYMBIOTEC PHARMALAB PRIVATE LTD (DMF 24691) and TIANJIN TIANYAO PHARMACEUTICALS CO LTD (DMF 35535). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Deflazacort records mean?
1 organisation has only inactive Type II DMFs for Deflazacort. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Deflazacort have a European Certificate of Suitability?
Yes. 1 organisation holds a valid CEP for Deflazacort on the EDQM register, including EUROAPI ITALY S.R.L. Brindisi (IT). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Deflazacort supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Deflazacort?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.